Agios Pharmaceuticals (AGIO) said Wednesday that the European Commission has granted orphan medicinal product designation to mitapivat, its oral small-molecule PK activator, for treating sickle cell disease.
The company said it plans to share results of its phase 3 study assessing the efficacy and safety of mitapivat in late 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments